BIO-TECHNE Corp vs ZIM Integrated Shipping Services Ltd — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.37B), while ZIM Integrated Shipping Services Ltd trades at $30.11 (market cap $3.61B). The key difference: BIO-TECHNE Corp is far larger — about 3.1× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays the higher dividend (20.16%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and ZIM Integrated Shipping Services Ltd for 27 Days on average.
| TECH | ZIM | |
|---|---|---|
Market Cap | $11.37B | $3.61B |
Volume | 3,153,511 | 1,800,267 |
Sector | Health | Industrials |
52-Week High | $72.61 | $30.51 |
52-Week Low | $43.31 | $12.44 |
Typical Hold Time | 63 Days | 27 Days |
Enterprise Value | $11.40B | $7.29B |
Dividend Yield | 0.44% | 20.16% |
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
ZIM trades at $29.99, up 2.71% today, near its 52-week high of $30.96. The stock shows a bullish technical trend with strong moving average signals. Fundamentally, Q2 2026 earnings beat estimates with $0.53 EPS versus a $0.02 loss expected, driven by higher freight rates and volumes. Revenue for 2025 was $6.9B with a net income of $479M, though 2026 projections show lower profitability. Recent news highlights a potential acquisition offer from Hapag-Lloyd at $35 per share, pending Israeli government approval.
The outlook is mixed: upside is capped by merger uncertainty and declining 2026 profit margins, but the acquisition premium offers potential gains. Risks include regulatory hurdles for the deal and volatile shipping rates. Analyst sentiment is cautious with no buy ratings, reflecting concerns over execution and external pressures. Investors should weigh the acquisition possibility against fundamental erosion.
Trailing returns across standard periods
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →